Clinical Trial: AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07584317) titled 'AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)' on May 07.

Brief Summary: This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in HCC.

Study Start Date: May 18

Study Type: OBSERVATIONAL

Condition: Hepatocellular Carcinoma

Intervention: OTHER: Artificial Intelligence

Investigators utilize a AI-based supportive system to predict clinical ...